News

Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in people with mild-to-moderate Alzheimer’s after 28 days of treatment, according to final data from a Phase 2b trial. Sumifilam, Cassava Sciences’ lead investigational candidate for…

A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease, allow the development of blood tests to accurately diagnose the disease at earlier stages. These are the findings of three studies presented during the recent Alzheimer’s Association International Conference (AAIC)…

Events are underway to mark World Alzheimer’s Month, observed every September to raise global awareness about the disease and challenge the stigma regarding dementia. September 21 has been designated World Alzheimer’s Day. Approximately 44 million people worldwide have Alzheimer’s disease, the most common form of dementia and an irreversible…

Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed an earlier study was pivotal. Results from this new efficacy trial, to open before year’s end,…

The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered…

To help accelerate the development of treatments for Alzheimer’s disease, the Alzheimer’s Association’s Part the Cloud research grant program is investing $24 million in clinical trials investigating 16 potential therapies. Scientists from around the world will use the funds to conduct Phase 1 and 2 trials…

A new non-invasive technique that can temporarily “open” the blood-brain barrier may make it easier for promising therapies to enter the brain of people with Alzheimer’s disease, a study reports.  The study, “Noninvasive…

People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at their doctor’s request. Under a special access scheme, the Therapeutic Goods Administration (TGA) — a…

Cortexyme has reached a milestone after enrolling 500 patients with mild to moderate Alzheimer’s disease in its ongoing Phase 2/3 GAIN clinical trial testing the company’s investigational treatment COR388 (atuzaginstat). Enrollment for GAIN (NCT03823404) has been open since the second quarter of 2019, with…

The Alzheimer’s Foundation of America (AFA) has awarded $518,391 in research grant funding to the Broad Institute and One Mind to study the role of the brain’s immune cells in the onset and progression of Alzheimer’s disease (AD). The hope is that, with more understanding…